Stevanato Group (STVN)
(Delayed Data from NYSE)
$19.66 USD
+0.46 (2.40%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $19.65 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STVN 19.66 +0.46(2.40%)
Will STVN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for STVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STVN
USNA vs. STVN: Which Stock Should Value Investors Buy Now?
USNA or STVN: Which Is the Better Value Stock Right Now?
STVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
TAK or STVN: Which Is the Better Value Stock Right Now?
Other News for STVN
Analysts Offer Insights on Healthcare Companies: Iradimed (IRMD), Stevanato Group (STVN) and Ascendis Pharma (ASND)
Morgan Stanley Keeps Their Hold Rating on Stevanato Group (STVN)
Analysts Offer Insights on Healthcare Companies: Stevanato Group (STVN), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)
Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fillĀ® Syringes and Cartridges
Stevanato: Destock Pressures, Long-Term Upside